On Tuesday, Edgewise Therapeutics Inc (NASDAQ: EWTX) opened lower -1.40% from the last session, before settling in for the closing price of $15.68. Price fluctuations for EWTX have ranged from $10.60 to $38.12 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -28.58% at the time writing. With a float of $73.99 million, this company’s outstanding shares have now reached $94.84 million.
Let’s determine the extent of company efficiency that accounts for 110 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Edgewise Therapeutics Inc (EWTX) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Edgewise Therapeutics Inc is 29.63%, while institutional ownership is 71.35%. The most recent insider transaction that took place on Apr 03 ’25, was worth 10,000,000. In this transaction Director of this company bought 496,771 shares at a rate of $20.13, taking the stock ownership to the 14,809,075 shares. Before that another transaction happened on Apr 03 ’25, when Company’s Director bought 496,771 for $20.13, making the entire transaction worth $10,000,000. This insider now owns 14,809,075 shares in total.
Edgewise Therapeutics Inc (EWTX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -28.58% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -12.71% during the next five years compared to -49.00% drop over the previous five years of trading.
Edgewise Therapeutics Inc (NASDAQ: EWTX) Trading Performance Indicators
Check out the current performance indicators for Edgewise Therapeutics Inc (EWTX). In the past quarter, the stock posted a quick ratio of 19.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.45, a number that is poised to hit -0.43 in the next quarter and is forecasted to reach -2.05 in one year’s time.
Technical Analysis of Edgewise Therapeutics Inc (EWTX)
Looking closely at Edgewise Therapeutics Inc (NASDAQ: EWTX), its last 5-days average volume was 0.96 million, which is a drop from its year-to-date volume of 1.59 million. As of the previous 9 days, the stock’s Stochastic %D was 91.37%. Additionally, its Average True Range was 1.44.
During the past 100 days, Edgewise Therapeutics Inc’s (EWTX) raw stochastic average was set at 19.52%, which indicates a significant decrease from 94.37% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 74.29% in the past 14 days, which was lower than the 85.43% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.71, while its 200-day Moving Average is $24.98. However, in the short run, Edgewise Therapeutics Inc’s stock first resistance to watch stands at $15.70. Second resistance stands at $15.95. The third major resistance level sits at $16.15. If the price goes on to break the first support level at $15.25, it is likely to go to the next support level at $15.05. Now, if the price goes above the second support level, the third support stands at $14.80.
Edgewise Therapeutics Inc (NASDAQ: EWTX) Key Stats
There are currently 104,774K shares outstanding in the company with a market cap of 1.63 billion. Presently, the company’s annual sales total 0 K according to its annual income of -133,810 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -39,660 K.
